Protein Therapeutics Market Research Report - Forecast till 2027

Protein Therapeutics Market Research Report: By Type (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon), Application (Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders), Protein Function (Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines), End User (Hospitals and Clinics, Specialty Centers,) - Forecast to 2027

ID: MRFR/HC/8664-HCR | February 2021 | Region: Global | 108 Pages         

Table of Contents

1. EXECUTIVE SUMMARY

1.1. Market Attractiveness Analysis

1.1.1. Global Protein Therapeutics Market, by Type

1.1.2. Global Protein Therapeutics Market, by Application

1.1.3. Global Protein Therapeutics Market, by Protein Function

1.1.4. Global Protein Therapeutics Market, by End User

1.1.5. Global Protein Therapeutics Market, by Region

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.3. Market Structure

2.4. Assumptions & Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Techniques

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.2.1. Increase in prevalence of chronic diseases

4.2.2. Growing adoption of plasma-derived therapies

4.2.3. Increasing awareness about protein therapeutics

4.3. Restraints

4.3.1. high cost of protein therapies

4.3.2. Unfavorable reimbursement scenario

4.4. Opportunities

4.4.1. XXX

5. MARKET FACTOR ANALYSIS

5.1. Supply Chain Analysis

5.1.1. R&D and Designing

5.1.2. Manufacturing

5.1.3. Distribution & Sales

5.1.4. Post Sales Services

5.2. Porter’s Five Forces Model

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Impact on Supply Chain

5.3.2. Impact on Production

5.3.3. Impact on Regions

5.3.4. Demand-Supply Gap Analysis

5.3.5. Impact on Pricing

6. GLOBAL PROTEIN THERAPEUTICS MARKET, BY TYPE

6.1. Overview

6.2. Monoclonal Antibodies

6.3. Insulin

6.4. Fusion Protein

6.5. Erythropoietin

6.6. Interferon

6.7. Human Growth Hormone

6.8. Follicle Stimulating Hormone

6.9. Others

7. GLOBAL PROTEIN THERAPEUTICS MARKET, BY APPLICATION

7.1. Overview

7.2. Cancer

7.3. Metabolic Disorders

7.4. Immunologic Disorders

7.5. Hematological Disorders

7.6. Others

8. GLOBAL PROTEIN THERAPEUTICS MARKET, BY PROTEIN FUNCTION

8.1. Overview

8.2. Enzymatic and regulatory activity

8.3. Special targeting activity

8.4. Vaccines

8.5. Others

9. GLOBAL PROTEIN THERAPEUTICS MARKET, BY END USER

9.1. Overview

9.2. Hospitals and Clinics

9.3. Specialty Centers

9.4. Others

10. GLOBAL PROTEIN THERAPEUTICS MARKET, BY REGION

10.1. Overview

10.2. Americas

10.2.1. Market Estimates & Forecast, by Type, 2017–2027

10.2.2. Market Estimates & Forecast, by Application, 2017–2027

10.2.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.2.4. Market Estimates & Forecast, by End User, 2017–2027

10.2.5. Market Estimates & Forecast, by Region, 2017–2027

10.2.5.1. North America

10.2.5.1.1. Market Estimates & Forecast, by Type, 2017–2027

10.2.5.1.2. Market Estimates & Forecast, by Application, 2017–2027

10.2.5.1.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.2.5.1.4. Market Estimates & Forecast, by End User, 2017–2027

10.2.5.1.5. Market Estimates & Forecast, by Country, 2017–2027

10.2.5.1.5.1. US

10.2.5.1.5.1.1. Market Estimates & Forecast, by Type, 2017–2027

10.2.5.1.5.1.2. Market Estimates & Forecast, by Application, 2017–2027

10.2.5.1.5.1.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.2.5.1.5.1.4. Market Estimates & Forecast, by End User, 2017–2027

10.2.5.1.5.2. Canada

10.2.5.1.5.2.1. Market Estimates & Forecast, by Type, 2017–2027

10.2.5.1.5.2.2. Market Estimates & Forecast, by Application, 2017–2027

10.2.5.1.5.2.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.2.5.1.5.2.4. Market Estimates & Forecast, by End User, 2017–2027

10.2.5.2. Latin America

10.2.5.2.1. Market Estimates & Forecast, by Type, 2017–2027

10.2.5.2.2. Market Estimates & Forecast, by Application, 2017–2027

10.2.5.2.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.2.5.2.4. Market Estimates & Forecast, by End User, 2017–2027

10.3. Europe

10.3.1. Market Estimates & Forecast, by Type, 2017–2027

10.3.2. Market Estimates & Forecast, by Application, 2017–2027

10.3.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.3.4. Market Estimates & Forecast, by End User, 2017–2027

10.3.5. Market Estimates & Forecast, by Region, 2017–2027

10.3.5.1. Western Europe

10.3.5.1.1. Market Estimates & Forecast, by Type, 2017–2027

10.3.5.1.2. Market Estimates & Forecast, by Application, 2017–2027

10.3.5.1.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.3.5.1.4. Market Estimates & Forecast, by End User, 2017–2027

10.3.5.1.5. Market Estimates & Forecast, by Country, 2017–2027

10.3.5.1.5.1. Germany

10.3.5.1.6. Market Estimates & Forecast, by Type, 2017–2027

10.3.5.1.7. Market Estimates & Forecast, by Application, 2017–2027

10.3.5.1.8. Market Estimates & Forecast, by Protein Function, 2017–2027

10.3.5.1.9. Market Estimates & Forecast, by End User, 2017–2027

10.3.5.1.9.1. France

10.3.5.1.10. Market Estimates & Forecast, by Type, 2017–2027

10.3.5.1.11. Market Estimates & Forecast, by Application, 2017–2027

10.3.5.1.12. Market Estimates & Forecast, by Protein Function, 2017–2027

10.3.5.1.13. Market Estimates & Forecast, by End User, 2017–2027

10.3.5.1.13.1. UK

10.3.5.1.14. Market Estimates & Forecast, by Type, 2017–2027

10.3.5.1.15. Market Estimates & Forecast, by Application, 2017–2027

10.3.5.1.16. Market Estimates & Forecast, by Protein Function, 2017–2027

10.3.5.1.17. Market Estimates & Forecast, by End User, 2017–2027

10.3.5.1.17.1. Italy

10.3.5.1.18. Market Estimates & Forecast, by Type, 2017–2027

10.3.5.1.19. Market Estimates & Forecast, by Application, 2017–2027

10.3.5.1.20. Market Estimates & Forecast, by Protein Function, 2017–2027

10.3.5.1.21. Market Estimates & Forecast, by End User, 2017–2027

10.3.5.1.21.1. Spain

10.3.5.1.22. Market Estimates & Forecast, by Type, 2017–2027

10.3.5.1.23. Market Estimates & Forecast, by Application, 2017–2027

10.3.5.1.24. Market Estimates & Forecast, by Protein Function, 2017–2027

10.3.5.1.25. Market Estimates & Forecast, by End User, 2017–2027

10.3.5.1.25.1. Rest of Western Europe

10.3.5.1.26. Market Estimates & Forecast, by Type, 2017–2027

10.3.5.1.27. Market Estimates & Forecast, by Application, 2017–2027

10.3.5.1.28. Market Estimates & Forecast, by Protein Function, 2017–2027

10.3.5.1.29. Market Estimates & Forecast, by End User, 2017–2027

10.3.6. Eastern Europe

10.3.6.1.1. Market Estimates & Forecast, by Type, 2017–2027

10.3.6.1.2. Market Estimates & Forecast, by Application, 2017–2027

10.3.6.1.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.3.6.1.4. Market Estimates & Forecast, by End User, 2017–2027

10.4. Asia-Pacific

10.4.1. Market Estimates & Forecast, by Type, 2017–2027

10.4.2. Market Estimates & Forecast, by Application, 2017–2027

10.4.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.4.4. Market Estimates & Forecast, by End User, 2017–2027

10.4.5. Market Estimates & Forecast, by Country, 2017–2027

10.4.5.1. China

10.4.5.1.1. Market Estimates & Forecast, by Type, 2017–2027

10.4.5.1.2. Market Estimates & Forecast, by Application, 2017–2027

10.4.5.1.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.4.5.1.4. Market Estimates & Forecast, by End User, 2017–2027

10.4.5.2. India

10.4.5.2.1. Market Estimates & Forecast, by Type, 2017–2027

10.4.5.2.2. Market Estimates & Forecast, by Application, 2017–2027

10.4.5.2.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.4.5.2.4. Market Estimates & Forecast, by End User, 2017–2027

10.4.5.3. Japan

10.4.5.3.1. Market Estimates & Forecast, by Type, 2017–2027

10.4.5.3.2. Market Estimates & Forecast, by Application, 2017–2027

10.4.5.3.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.4.5.3.4. Market Estimates & Forecast, by End User, 2017–2027

10.4.5.4. Australia

10.4.5.4.1. Market Estimates & Forecast, by Type, 2017–2027

10.4.5.4.2. Market Estimates & Forecast, by Application, 2017–2027

10.4.5.4.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.4.5.4.4. Market Estimates & Forecast, by End User, 2017–2027

10.4.5.5. South Korea

10.4.5.5.1. Market Estimates & Forecast, by Type, 2017–2027

10.4.5.5.2. Market Estimates & Forecast, by Application, 2017–2027

10.4.5.5.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.4.5.5.4. Market Estimates & Forecast, by End User, 2017–2027

10.4.5.6. Rest of Asia-Pacific

10.4.5.6.1. Market Estimates & Forecast, by Type, 2017–2027

10.4.5.6.2. Market Estimates & Forecast, by Application, 2017–2027

10.4.5.6.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.4.5.6.4. Market Estimates & Forecast, by End User, 2017–2027

10.5. Middle East & Africa

10.5.1. Market Estimates & Forecast, by Type, 2017–2027

10.5.2. Market Estimates & Forecast, by Application, 2017–2027

10.5.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.5.4. Market Estimates & Forecast, by End User, 2017–2027

10.5.5. Market Estimates & Forecast, by Region, 2017–2027

10.5.5.1. Middle East

10.5.5.1.1. Market Estimates & Forecast, by Type, 2017–2027

10.5.5.1.2. Market Estimates & Forecast, by Application, 2017–2027

10.5.5.1.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.5.5.1.4. Market Estimates & Forecast, by End User, 2017–2027

10.5.5.2. Africa

10.5.5.2.1. Market Estimates & Forecast, by Type, 2017–2027

10.5.5.2.2. Market Estimates & Forecast, by Application, 2017–2027

10.5.5.2.3. Market Estimates & Forecast, by Protein Function, 2017–2027

10.5.5.2.4. Market Estimates & Forecast, by End User, 2017–2027

11. COMPETITIVE LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market Share Analysis

11.4. Major Growth Strategy in the global Protein Therapeutics market

11.5. Competitive Benchmarking

11.6. Leading Player in terms of Number of Developments in global protein therapeutics market

11.7. Key Developments & Growth Strategies

11.7.1. New Product Launch

11.7.2. Merger & Acquisition

11.7.3. Joint Ventures

11.8. Major Players Financial Matrix & Market Ratio

11.8.1. Sales & Operating Income, 2019

11.8.2. Major Players R&D Expenditure, 2019

12. COMPANY PROFILES

12.1. Abbott Laboratories

12.1.1. Company Overview

12.1.2. Financial Overview

12.1.3. Products Offered

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Amgen Inc.

12.3. Baxter International Inc.

12.4. Eli Lilly and Company

12.5. F. Hoffmann-La Roche Ltd.

12.6. Johnson & Johnson

12.7. Merck & Co., Inc.

12.8. Novo Nordisk A/S

12.9. CSL Behring

12.10. Bristol Myers Squibb Co.

12.11. Pfizer Inc.

12.12. Sanofi.

12.13. Biogen, Inc

12.14. Others

13. APPENDIX

13.1. References

13.2. Related Reports

NOTE:

This table of content is tentative and subject to change as the research progresses.

ο‚‘ In section 12, each company will be profiled based on the Market Overview, Financials, and Product Portfolio, Business Strategies, and Recent Developments parameters.

ο‚‘ Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.

Protein Therapeutics Market

The Protein Therapeutics Market is expected to cross USD 290,691.88 Million by 2027 at a CAGR of 6.86%.

Segmentation

By Type Monoclonal Antibodies Insulin Fusion Protein Erythropoietin Interferon
By Application Cancer Metabolic Disorders Immunologic Disorders Hematological Disorders
By End User Hospitals And Clinics Specialty Centers

Key Players

  • Abbott Laboratories (US)
  • Amgen Inc. (US)
  • Baxter International Inc. (US)
  • Eli Lilly and Company (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Johnson & Johnson (US)
  • Merck & Co. Inc. (US)
  • Novo Nordisk A/S (Denmark)
  • CSL Behring (US)
  • Bristol Myers Squibb Co. (US)
  • Pfizer Inc (US)
  • Sanofi (France)

Drivers

  • he rapid technological advancements in the field of protein therapeutics are likely to impact their demand positively.
  • The increasing government initiatives for the development of the healthcare sector is expected to provide favorable conditions for the growth of the market.
Speak to Analyst Request a Free Sample

Protein Therapeutics Market Forecast


Protein Therapeutics Market is expected to cross USD 290,691.88 Million by 2027 at a CAGR of 6.86%.


Market Synopsis


Therapeutic protein drugs is one of the important class of medicines. These drugs are used in the treatment and management of different diseases, such as cancer and infectious diseases. Protein therapeutic drugs have significant potential to improve human health, and hence in the future, the demand for these drugs is likely to increase significantly.


Market Influencer


The rising prevalence of chronic disorders such as diabetes is expected to influence the protein therapeutics market growth during the forecast period. According to the report published by The International Diabetes Federation (IDF), in 2019, around 463 million adults (20-79 years) had diabetes, and by the end of 2045, this number is expected to reach 700 million. Similarly, other chronic disorders are growing at a high rate, which is likely to influence the demand for protein therapeutics around the world in the coming years.


Protein Therapeutics Market Drivers



  • The rapid technological advancements in the field of protein therapeutics are likely to impact their demand positively. The monoclonal antibodies (MABs) are widely used in the treatment of several diseases. Alemtuzumab, Bevacizumab, Cetuximab, Gemtuzumab ozogamicin, Ipilimumab, Ofatumumab, Panitumumab, Pembrolizumab, Ranibizumab, Rituximab, and Trastuzumab are FDA approved MABs used in the treatment of cancer.



  • The rising awareness of protein therapeutics is also expected to drive the growth of the global protein therapeutics market during the forecast period.



  • The growing adoption of plasma-derived therapies for the management of chronic disorders is likely to encourage protein therapeutics market growth in the near future.



  • The increasing government initiatives for the development of the healthcare sector is expected to provide favorable conditions for the growth of the protein therapeutics market. For instance, in July 2018, the Ministry of Health and Family Welfare (MoHFW), Government of India launched The National Viral Hepatitis Control Program for the management of Hepatitis A, B, C, D & E, which is expected to provide favorable conditions for the growth of the protein therapeutics market.


Market Restraints



  • The stringent regulatory framework related to product approval is expected to curb protein therapeutics market growth during the forecast period.



  • The high cost of protein therapies is expected to restrain the protein therapeutics market growth.


Segmentation


By Type



  • Monoclonal Antibodies: Monoclonal antibodies (MABs) are developed from a similar parent immune cell to target and recognize specific cells. These antigens act as antibodies in tandem with the human immune system against them. MABs are used to treat medical complications related to substance abuse, cancer, asthma, viral infection, septicemia, and poisoning. It is the fastest-growing segment in the protein therapeutics market.



  • Insulin: It is a hormone that plays an important role in controlling blood glucose levels. The shortage of insulin or an inability to react to insulin can lead to the development of the symptoms of diabetes. Insulin is vital in the management of diabetes and related complications. It is the fastest-growing segment in the protein therapeutics market.



  • Fusion Protein: The fusion of two different genes manufactures the fusion proteins. These are widely used in the treatment of cancer.



  • Erythropoietin: Erythropoietin is a hormone produced by the kidney, which promotes the formation of red blood cells by the bone marrow and has various therapeutic applications.



  • Interferon: Interferons is a group of signaling proteins synthesized and released by host cells in response to protect against several viruses. It can be used in the treatment of multiple sclerosis (MS), hepatitis C, and several forms of cancer.



  • Human Growth Hormone: The growth hormone is a small protein formed in the pituitary gland and secreted into the bloodstream. Its production is controlled by a complex set of hormones synthesized in the hypothalamus of the brain and the intestinal tract and pancreas.



  • Follicle Stimulating Hormone: the pituitary gland produces Follicle-stimulating hormone. It is an important hormone for normal functioning of the reproductive system in men and women.



  • Others


By Application



  • Cancer: It is the largest segment and is expected to register the highest CAGR during the forecast period. The rising prevalence of cancer is increasing the demand for protein therapeutics market. According to the International Agency for Research on Cancer, in 2018, around 1,80,78,957 cases of cancer were detected across the globe. This is expected to drive the growth of this segment during the forecast period.



  • Metabolic Disorders: Metabolic disorders are closely related to the liver or pancreas. The increasing prevalence of metabolic disorders such as diabetes, heart attack, and Gaucher’s disease is likely to drive protein therapeutics market growth during the forecast period.



  • Immunologic Disorders: It includes rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, and others.



  • Hematological Disorders: Acute lymphoblastic leukemia, anemia, deep vein thrombosis, Hodgkin's lymphoma, thrombocythemia and thrombocytosis, and others are covered in this segment.



  • Others: others contain hormonal disorders, genetic disorders, and others


By Protein Function



  • Enzymatic and Regulatory Activity: These proteins replace a protein that is inadequate or abnormal, up-regulate an existing pathway, or provide a new function or activity. This is the fastest-growing segment in the protein therapeutics market.



  • Special Targeting Activity: Therapeutic proteins have special targeting activity properties. They can interfere with a molecule or organism or deliver other molecules and widely used for treatment purposes.



  • Vaccines: Therapeutic proteins are used for manufacturing vaccines. They provide protection against foreign agents, autoimmune diseases, and cancer.



  • Others


By End-User



  • Hospitals and Clinics: It is the largest segment and is expected to register the highest CAGR during the forecast period. The increasing demand for protein therapeutics products is expected to drive the growth of this segment.



  • Specialty Centers: The increasing development in the healthcare sector and the growing government initiatives are expected to drive the growth of this segment.



  • Others: It includes research organizations and academic institutes.


By Region



  • Americas: It is the largest regional market. The increasing government initiatives and the rising concerns in terms of health and safety of healthcare professionals are boosting the demand for therapeutic proteins. Also, the rising prevalence of cancer is one of the major factors responsible for the growth of the protein therapeutics market during the forecast period. According to the National Cancer Institute, it was estimated that 1,735,350 new cases of cancer were diagnosed in the US in 2018. Additionally, according to the American Cancer Society, Inc., it was determined that 1,762,450 new cancer cases were diagnosed in the US in 2019. Such a large patient population is predicted to entitle considerable growth of the global protein therapeutics market in the near future.



  • Europe: The healthcare market in western European that includes Germany, the UK, France, and Italy is expected to exhibit an increase in healthcare expenditure, increasing cases of rheumatoid arthritis, multiple sclerosis, and chronic inflammatory demyelinating polyneuropathy thereby resulting in the growth of the protein therapeutics market during the forecast period. According to the report published by the National Rheumatoid Arthritis Society, around 400,000 patients had rheumatoid arthritis in 2018. It is likely to boost the protein therapeutics market growth during the forecast period.



  • Asia-Pacific: It is the fastest-growing regional market. Emerging market players in the untapped region, increasing R&D in the protein therapeutics segment, rising focus of government toward vaccination to prevent various diseases, and huge target population are some of the factors influencing the market growth. For instance, the Japanese government has been providing free hepatitis testing since 2002 for all citizens between 40 and 70 years of age as part of routine health check-up and started a special subsidy program in 2008 to reduce the burden of out-of-pocket costs by patients. The growing geriatric population is one of the major factors driving the protein therapeutics market growth in the region. According to the Asian Development Bank, Asia's elderly population is projected to reach nearly 923 million by 2050. India, China, and Japan are the major revenue contributors to the protein therapeutics market growth.



  • Middle East & Africa: The government initiatives and increasing investments in the healthcare sector of the UAE and South Africa are expected to drive the growth of the protein therapeutics market in this region.


Protein Therapeutics Market Key Players



  • Abbott Laboratories

  • Amgen Inc.

  • Baxter International Inc.

  • Eli Lilly and Company

  • Hoffmann-La Roche Ltd

  • Johnson & Johnson

  • Merck & Co., Inc.

  • Novo Nordisk A/S

  • CSL Behring

  • Bristol Myers Squibb Co.

  • Pfizer Inc.

  • Biogen, Inc.

  • Others



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: USD 290,691.88 Million
  CAGR   6.86% (2020-2027)
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Application, Protein Function, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott Laboratories (US), Amgen Inc. (US), Baxter International Inc. (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Johnson & Johnson (US), Merck & Co., Inc. (US), Novo Nordisk A/S (Denmark), CSL Behring (US), Bristol Myers Squibb Co. (US), Pfizer Inc. (US), Sanofi (France), and Biogen, Inc. (US).
  Key Market Opportunities

  • The rising awareness of protein therapeutics is also expected to drive the growth of the global market during the forecast period.
  • The growing adoption of plasma-derived therapies for the management of chronic disorders is likely to encourage market growth in the near future.
  •   Key Market Drivers

  • The rapid technological advancements in the field of protein therapeutics are likely to impact their demand positively.
  • The increasing government initiatives for the development of the healthcare sector is expected to provide favorable conditions for the growth of the market.


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Protein Therapeutics Market is anticipated to hold a value of USD 290,691.88 million by 2027.

    Protein Therapeutics Market is anticipated to thrive at a CAGR of 6.86% by 2027.

    The swift technological development in the field of protein therapeutics is anticipated to be one of the most important factors driving the Global Protein Therapeutics Market.

    Protein Therapeutics Market can be segmented on the basis of type, application, end-user, protein function, and region.

    Abbott Laboratories, Biogen, Inc., Amgen Inc., Baxter International Inc., Johnson & Johnson, Eli Lilly and Company, Hoffmann-La Roche Ltd, Merck & Co., Inc., Bristol Myers Squibb Co., Novo Nordisk A/S, CSL Behring, Pfizer Inc., and others are some of the eminent players of the Global Protein Therapeutics Market.